RPG Life Sciences Future Growth

Future criteria checks 0/6

We currently don't have sufficient analyst coverage to forecast growth and revenue for RPG Life Sciences.

Key information

n/a

Earnings growth rate

n/a

EPS growth rate

Pharmaceuticals earnings growth	17.5%
Revenue growth rate	n/a
Future return on equity	n/a
Analyst coverage	None
Last updated	n/a

Recent future growth updates

No updates

Recent updates

There May Be Some Bright Spots In RPG Life Sciences' (NSE:RPGLIFE) Earnings

Nov 15

RPG Life Sciences Limited's (NSE:RPGLIFE) Shares Climb 26% But Its Business Is Yet to Catch Up

Oct 18

Investors Appear Satisfied With RPG Life Sciences Limited's (NSE:RPGLIFE) Prospects As Shares Rocket 30%

Jul 25

Shareholders May Be More Conservative With RPG Life Sciences Limited's (NSE:RPGLIFE) CEO Compensation For Now

Aug 24

A Look At The Intrinsic Value Of RPG Life Sciences Limited (NSE:RPGLIFE)

Jun 14

Are Strong Financial Prospects The Force That Is Driving The Momentum In RPG Life Sciences Limited's NSE:RPGLIFE) Stock?

Feb 09

Can You Imagine How RPG Life Sciences' (NSE:RPGLIFE) Shareholders Feel About The 75% Share Price Increase?

Jan 13

RPG Life Sciences (NSE:RPGLIFE) Is Growing Earnings But Are They A Good Guide?

Dec 23

Declining Stock and Solid Fundamentals: Is The Market Wrong About RPG Life Sciences Limited (NSE:RPGLIFE)?

Nov 11

Estimating The Fair Value Of RPG Life Sciences Limited (NSE:RPGLIFE)

Oct 21

Did Business Growth Power RPG Life Sciences' (NSE:RPGLIFE) Share Price Gain of 126%?

Sep 28

What Makes RPG Life Sciences Limited (NSE:RPGLIFE) A Great Dividend Stock?

Aug 31

With RPG Life Sciences Limited (NSE:RPGLIFE) It Looks Like You'll Get What You Pay For

Aug 11

What You Can Learn From RPG Life Sciences Limited's (NSE:RPGLIFE) P/E

Jul 28

Calculating The Intrinsic Value Of RPG Life Sciences Limited (NSE:RPGLIFE)

Jul 10

In this section we usually present revenue and earnings growth projections based on the consensus estimates of professional analysts to help investors understand the company’s ability to generate profit. But as RPG Life Sciences has not provided enough past data and has no analyst forecast, its future earnings cannot be reliably calculated by extrapolating past data or using analyst predictions.

This is quite a rare situation as 97% of companies covered by SimplyWall St do have past financial data.

Earnings and Revenue Growth Forecasts

NSEI:RPGLIFE - Analysts future estimates and past financials data (INR Millions)
Date	Revenue	Earnings	Free Cash Flow	Cash from Op	Avg. No. Analysts
9/30/2024	6,183	707	444	1,065	N/A
6/30/2024	5,997	923	N/A	N/A	N/A
3/31/2024	5,821	877	251	944	N/A
12/31/2023	5,736	848	N/A	N/A	N/A
9/30/2023	5,505	774	354	896	N/A
6/30/2023	5,317	715	N/A	N/A	N/A
3/31/2023	5,128	676	581	908	N/A
12/31/2022	4,981	648	N/A	N/A	N/A
9/30/2022	4,831	603	343	612	N/A
6/30/2022	4,610	561	N/A	N/A	N/A
3/31/2022	4,402	515	408	648	N/A
12/31/2021	4,291	509	N/A	N/A	N/A
9/30/2021	4,211	491	696	808	N/A
6/30/2021	4,056	445	N/A	N/A	N/A
3/31/2021	3,891	400	498	583	N/A
12/31/2020	3,851	361	N/A	N/A	N/A
9/30/2020	3,718	311	239	316	N/A
6/30/2020	3,732	297	N/A	N/A	N/A
3/31/2020	3,756	290	394	502	N/A
12/31/2019	3,557	276	N/A	N/A	N/A
9/30/2019	3,523	249	458	675	N/A
6/30/2019	3,443	173	N/A	N/A	N/A
3/31/2019	3,302	108	261	458	N/A
12/31/2018	3,448	105	N/A	N/A	N/A
9/30/2018	3,495	107	N/A	N/A	N/A
6/30/2018	3,485	149	N/A	N/A	N/A
3/31/2018	3,440	135	N/A	147	N/A
12/31/2017	3,360	141	N/A	N/A	N/A
9/30/2017	3,062	97	N/A	N/A	N/A
6/30/2017	2,948	62	N/A	N/A	N/A
3/31/2017	2,936	121	N/A	73	N/A
12/31/2016	3,029	229	N/A	N/A	N/A
9/30/2016	3,095	270	N/A	N/A	N/A
6/30/2016	2,993	194	N/A	N/A	N/A
3/31/2016	2,552	84	N/A	328	N/A
12/31/2015	2,758	141	N/A	N/A	N/A
9/30/2015	2,609	119	N/A	N/A	N/A
6/30/2015	2,501	20	N/A	N/A	N/A
3/31/2015	2,423	10	N/A	-20	N/A
12/31/2014	2,290	-42	N/A	N/A	N/A
9/30/2014	2,273	-98	N/A	N/A	N/A
6/30/2014	2,312	-1	N/A	N/A	N/A
3/31/2014	2,356	534	N/A	-56	N/A
12/31/2013	2,400	613	N/A	N/A	N/A

Analyst Future Growth Forecasts

Earnings vs Savings Rate: Insufficient data to determine if RPGLIFE's forecast earnings growth is above the savings rate (6.7%).

Earnings vs Market: Insufficient data to determine if RPGLIFE's earnings are forecast to grow faster than the Indian market

High Growth Earnings: Insufficient data to determine if RPGLIFE's earnings are expected to grow significantly over the next 3 years.

Revenue vs Market: Insufficient data to determine if RPGLIFE's revenue is forecast to grow faster than the Indian market.

High Growth Revenue: Insufficient data to determine if RPGLIFE's revenue is forecast to grow faster than 20% per year.

Earnings per Share Growth Forecasts

Future Return on Equity

Future ROE: Insufficient data to determine if RPGLIFE's Return on Equity is forecast to be high in 3 years time

Discover growth companies

Company Analysis and Financial Data Status

Data	Last Updated (UTC time)
Company Analysis	2024/12/28 16:35
End of Day Share Price	2024/12/27 00:00
Earnings	2024/09/30
Annual Earnings	2024/03/31

Data Sources

The data used in our company analysis is from S&P Global Market Intelligence LLC. The following data is used in our analysis model to generate this report. Data is normalised which can introduce a delay from the source being available.

Package	Data	Timeframe	Example US Source ^*
Company Financials	10 years	Income statement Cash flow statement Balance sheet	SEC Form 10-K SEC Form 10-Q
Analyst Consensus Estimates	+3 years	Forecast financials Analyst price targets	Analyst Research Reports Blue Matrix
Market Prices	30 years	Stock prices Dividends, Splits and Actions	ICE Market Data SEC Form S-1
Ownership	10 years	Top shareholders Insider trading	SEC Form 4 SEC Form 13D
Management	10 years	Leadership team Board of directors	SEC Form 10-K SEC Form DEF 14A
Key Developments	10 years	Company announcements	SEC Form 8-K

^* example for US securities, for non-US equivalent regulatory forms and sources are used.

Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more here.

Analysis Model and Snowflake

Details of the analysis model used to generate this report is available on our Github page, we also have guides on how to use our reports and tutorials on Youtube.

Learn about the world class team who designed and built the Simply Wall St analysis model.

Industry and Sector Metrics

Our industry and section metrics are calculated every 6 hours by Simply Wall St, details of our process are available on .

Analyst Sources

RPG Life Sciences Limited is covered by 2 analysts. 0 of those analysts submitted the estimates of revenue or earnings used as inputs to our report. Analysts submissions are updated throughout the day.

Analyst	Institution
Kunal Dhamesha	Emkay Global Financial Services Ltd.
Kameswari V. S. Chavali	FirstCall Research

RPG Life Sciences Future Growth

Future criteria checks 0/6

Key information

Recent future growth updates

Recent updates

There May Be Some Bright Spots In RPG Life Sciences' (NSE:RPGLIFE) Earnings

Investor sentiment deteriorates as stock falls 19%

Second quarter 2025 earnings released: EPS: ₹2.54 (vs ₹15.64 in 2Q 2024)

RPG Life Sciences Limited to Report Q2, 2025 Results on Nov 07, 2024

Investor sentiment deteriorates as stock falls 16%

RPG Life Sciences Limited's (NSE:RPGLIFE) Shares Climb 26% But Its Business Is Yet to Catch Up

Investor sentiment improves as stock rises 15%

Rpg Life Sciences Limited Announces Board Changes

Investors Appear Satisfied With RPG Life Sciences Limited's (NSE:RPGLIFE) Prospects As Shares Rocket 30%

RPG Life Sciences Limited Declares Equity Dividend for the Year Ended March 31, 2024

Investor sentiment improves as stock rises 17%

RPG Life Sciences Limited to Report Q1, 2025 Results on Jul 19, 2024

Full year 2024 earnings released: EPS: ₹53.00 (vs ₹40.90 in FY 2023)

Upcoming dividend of ₹16.00 per share

RPG Life Sciences Limited, Annual General Meeting, Jul 16, 2024

RPG Life Sciences' (NSE:RPGLIFE) Earnings Are Of Questionable Quality

RPG Life Sciences Limited Recommends Equity Dividend for the Year Ended March 31, 2024

Full year 2024 earnings released: EPS: ₹53.01 (vs ₹40.90 in FY 2023)

RPG Life Sciences Limited to Report Q4, 2024 Results on Apr 30, 2024

Third quarter 2024 earnings released: EPS: ₹16.00 (vs ₹11.56 in 3Q 2023)

RPG Life Sciences Limited to Report Nine Months, 2024 Results on Feb 01, 2024

Second quarter 2024 earnings released: EPS: ₹15.64 (vs ₹12.08 in 2Q 2023)

Investor sentiment improves as stock rises 16%

RPG Life Sciences Limited to Report Q2, 2024 Results on Oct 18, 2023

RPG Life Sciences Limited Approves Dividend for the Financial Year Ended March 31, 2023

RPG Life Sciences Limited to Report Q1, 2024 Results on Jul 28, 2023

Full year 2023 earnings released: EPS: ₹40.90 (vs ₹31.13 in FY 2022)

Upcoming dividend of ₹12.00 per share at 1.2% yield

RPG Life Sciences (NSE:RPGLIFE) Is Increasing Its Dividend To ₹12.00

RPG Life Sciences Limited Recommends Payment of Final Dividend for the Financial Year 2022-23

Investor sentiment improves as stock rises 16%

Full year 2023 earnings released: EPS: ₹40.90 (vs ₹31.13 in FY 2022)

Third quarter 2023 earnings released: EPS: ₹11.56 (vs ₹8.85 in 3Q 2022)

RPG Life Sciences Limited to Report Q3, 2023 Results on Feb 01, 2023

Insufficient new directors

Insufficient new directors

Second quarter 2023 earnings released: EPS: ₹12.08 (vs ₹9.52 in 2Q 2022)

RPG Life Sciences Limited to Report Q2, 2023 Results on Oct 17, 2022

Estimating The Intrinsic Value Of RPG Life Sciences Limited (NSE:RPGLIFE)

RPG Life Sciences Limited Approves Dividend for the Financial Year Ended March 31, 2022

RPG Life Sciences Limited to Report Q1, 2023 Results on Aug 02, 2022

Full year 2022 earnings released: EPS: ₹31.13 (vs ₹24.19 in FY 2021)

Upcoming dividend of ₹9.60 per share

RPG Life Sciences Limited Proposes Final Dividend for the Financial Year Ended March 31, 2022

Now 20% undervalued

Now 21% undervalued

Now 21% undervalued after recent price drop

Full year 2022 earnings released: EPS: ₹31.13 (vs ₹24.19 in FY 2021)

RPG Life Sciences Limited to Report Q4, 2022 Results on Apr 29, 2022

Investor sentiment improved over the past week

Third quarter 2022 earnings: Revenues and EPS in line with analyst expectations

Second quarter 2022 earnings released: EPS ₹9.52 (vs ₹6.74 in 2Q 2021)

Investor sentiment improved over the past week

Investor sentiment improved over the past week

Shareholders May Be More Conservative With RPG Life Sciences Limited's (NSE:RPGLIFE) CEO Compensation For Now

First quarter 2022 earnings released: EPS ₹8.21 (vs ₹5.48 in 1Q 2021)

A Look At The Intrinsic Value Of RPG Life Sciences Limited (NSE:RPGLIFE)

Full year 2021 earnings released: EPS ₹24.19 (vs ₹17.54 in FY 2020)

RPG Life Sciences Limited Recommends Equity Dividend for the Financial Year Ended March 31, 2021

Are Strong Financial Prospects The Force That Is Driving The Momentum In RPG Life Sciences Limited's NSE:RPGLIFE) Stock?

New 90-day high: ₹406

RPG Life Sciences Limited to Report Q3, 2021 Results on Jan 25, 2021

Can You Imagine How RPG Life Sciences' (NSE:RPGLIFE) Shareholders Feel About The 75% Share Price Increase?

RPG Life Sciences (NSE:RPGLIFE) Is Growing Earnings But Are They A Good Guide?

Declining Stock and Solid Fundamentals: Is The Market Wrong About RPG Life Sciences Limited (NSE:RPGLIFE)?

First half earnings released

Estimating The Fair Value Of RPG Life Sciences Limited (NSE:RPGLIFE)

Did Business Growth Power RPG Life Sciences' (NSE:RPGLIFE) Share Price Gain of 126%?

New 90-day high: ₹405

What Makes RPG Life Sciences Limited (NSE:RPGLIFE) A Great Dividend Stock?

With RPG Life Sciences Limited (NSE:RPGLIFE) It Looks Like You'll Get What You Pay For

What You Can Learn From RPG Life Sciences Limited's (NSE:RPGLIFE) P/E

RPG Life Sciences Limited to Report Q1, 2021 Results on Jul 31, 2020

Calculating The Intrinsic Value Of RPG Life Sciences Limited (NSE:RPGLIFE)

Earnings and Revenue Growth Forecasts